AV
AVXL.US Anavex Life Sciences Corp
- Market cap
- USD 86.5M
- P/E
- -
- P/B
- 0.81x
- ROE
- -3.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is AVXL.US undervalued?
Graham numberThe Graham number of Anavex Life Sciences Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Anavex Life Sciences Corp fundamental analysis
No fundamental analysis for Anavex Life Sciences Corp yet.
Anavex Life Sciences Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Anavex Life Sciences Corp
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's dis…
Full company profileAnavex Life Sciences Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Anavex Life Sciences Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | -685K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.25K | 0.00 | 0.00 | - | - | - | - | - | - | - | - |
| Operating Income | -15.6M | -15.5M | -19.2M | -28.8M | -31.1M | -42.0M | -51.0M | -47.5M | -52.9M | -51.4M | -8.71M |
| EBITDA | -15.0M | -15.6M | -19.1M | -28.9M | -31.1M | -37.6M | -47.6M | -47.5M | -43.0M | -46.4M | -5.76M |
| Net Income | -14.7M | -13.5M | -17.5M | -26.3M | -26.3M | -37.9M | -48.0M | -47.5M | -43.0M | -46.4M | -4.26M |
| EPS | -0.42 | -0.33 | -0.39 | -0.54 | -0.45 | -0.54 | -0.62 | -0.60 | -0.52 | -0.54 | -0.05 |
| Balance Sheet | |||||||||||
| Total Assets | 9.50M | 27.8M | 24.4M | 25.3M | 34.5M | 162M | 153M | 154M | 136M | 104M | 120M |
| Total Liabilities | 3.19M | 3.58M | 3.88M | 5.04M | 7.31M | 10.8M | 10.2M | 12.5M | 15.3M | 8.95M | 7.69M |
| Shareholders' Equity | 6.31M | 24.3M | 20.5M | 20.3M | 27.2M | 151M | 142M | 142M | 120M | 94.9M | 112M |
| Cash & Short-term Investments | 9.19M | 27.4M | 22.9M | 22.2M | 29.2M | 152M | 149M | 151M | 132M | 103M | 118M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -9.24M | -9.02M | -12.6M | -18.5M | -21.3M | -30.4M | -24.2M | -27.8M | -30.8M | -39.0M | -33.5M |
| Capital Expenditure | 3.02K | 0.00 | 0.00 | 0.00 | 4.00 | 4.00 | 4.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -9.24M | -9.02M | -12.6M | -18.5M | -21.3M | -30.4M | -24.2M | -27.8M | -30.8M | -39.0M | -33.5M |
| Ratios | |||||||||||
| ROE | -233.6% | -55.5% | -85.2% | -129.6% | -96.5% | -25.1% | -33.7% | -33.5% | -35.8% | -48.9% | -3.8% |
| ROA | -155.1% | -48.4% | -71.6% | -103.8% | -76.1% | -23.5% | -31.4% | -30.8% | -31.7% | -44.7% | -3.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Anavex Life Sciences Corp dividends
Anavex Life Sciences Corp has not paid dividends in the last 9 fiscal years.
Last stock split: 1:4 on Oct 7, 2015.
Who owns Anavex Life Sciences Corp
- Insiders 1.71%
- Institutions 41.65%
- Public & others 56.64%
- Shares outstanding 92.7M
- Free float 89.8M
Top funds holding AVXL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.93M | 3.16% | 0.00% | Sep 2026 |
| Federated Hermes MDT Small Cap Core IS | 2.58M | 2.79% | +141.80% | Sep 2026 |
| iShares Russell 2000 ETF | 2.36M | 2.55% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 1.03M | 1.11% | +2.73% | Aug 2026 |
| iShares Russell 2000 Value ETF | 737K | 0.80% | 0.00% | Oct 2026 |
| iShares Biotechnology ETF | 697K | 0.75% | -0.19% | Oct 2026 |
| Vanguard Russell 2000 ETF | 534K | 0.58% | +0.79% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 492K | 0.53% | +0.23% | Oct 2026 |
| Fidelity Extended Market Index | 437K | 0.47% | +9.86% | Sep 2026 |
| iShares Micro-Cap ETF | 277K | 0.30% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 271K | 0.29% | +0.11% | Sep 2026 |
| Schwab Small Cap Index | 225K | 0.24% | 0.00% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 206K | 0.22% | -6.51% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 205K | 0.22% | -0.38% | Oct 2026 |
| Fidelity Total Market Index | 176K | 0.19% | -0.05% | Sep 2026 |
| iShares U.S. Small-Cap Eq Fac ETF | 175K | 0.19% | 0.00% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 163K | 0.18% | -12.66% | Sep 2026 |
| Fidelity Series Total Market Index | 140K | 0.15% | 0.00% | Sep 2026 |
| iShares Core S&P Total US Stock Mkt ETF | 125K | 0.13% | +0.03% | Oct 2026 |
| Nuveen Small Cap Blend Idx R6 | 122K | 0.13% | 0.00% | Aug 2026 |
Top institutions holding AVXL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 8.06M | 8.69% | +5.86% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.05M | 4.37% | +4.93% | Jun 2026 |
| Two Sigma Investments LLC | 3.05M | 3.29% | -6.20% | Jun 2026 |
| Geode Capital Management, LLC | 2.41M | 2.60% | +10.02% | Jun 2026 |
| State Street Corp | 1.92M | 2.07% | -57.39% | Jun 2026 |
| Federated Hermes Inc | 1.07M | 1.16% | +101.37% | Jun 2026 |
| AQR Capital Management LLC | 963K | 1.04% | +27.25% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 949K | 1.02% | +21.13% | Jun 2026 |
| Summit Financial LLC | 909K | 0.98% | -3.30% | Jun 2026 |
| The Goldman Sachs Group Inc | 891K | 0.96% | +10.72% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 890K | 0.96% | +112.05% | Jun 2026 |
| Northern Trust Corp | 784K | 0.85% | +8.18% | Jun 2026 |
| Barclays PLC | 754K | 0.81% | +40.12% | Jun 2026 |
| Charles Schwab Investment Management Inc | 735K | 0.79% | -2.88% | Jun 2026 |
| Bank of America Corp | 654K | 0.71% | -24.20% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 621K | 0.67% | -3.97% | Jun 2026 |
| UBS Group AG | 620K | 0.67% | +8.85% | Jun 2026 |
| Private Advisor Group, LLC | 504K | 0.54% | +0.86% | Jun 2026 |
| LPL Financial Corp | 406K | 0.44% | -2.99% | Jun 2026 |
| Stifel Financial Corp | 333K | 0.36% | +40.45% | Jun 2026 |
Anavex Life Sciences Corp company profile
- Company name
- Anavex Life Sciences Corp
- Ticker
- AVXL.US
- Exchange
- USA Stocks
- Listed since
- Aug 2, 2006
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 34
- Fiscal year end
- September
- Address
- 630 5th Avenue, New York, NY, United States, 10111
- Phone
- 844 689 3939
- Website
- anavex.com
About Anavex Life Sciences Corp
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, as well as exhibits anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71 that targets SIGMAR1 and M1 muscarinic receptors, which is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, such as cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Anavex Life Sciences Corp management
2- Ms. Sandra Boenisch CPA, CGAPrincipal Financial Officer & Treasurer · born 1981
- Dr. Terrie Kellmeyer Ph.D.CEO, President & Director · born 1967